APA

Shultz D. B., Pai J., Chiu W., Ng K., Hellendag M. G., Heestand G., Chang D. T., Tu D., Moore M. J., Parulekar W. R. & Koong A. C. (20160708). A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. : PloS one.

Chicago

Shultz David B, Pai Jonathan, Chiu Wayland, Ng Kendall, Hellendag Madeline G, Heestand Gregory, Chang Daniel T, Tu Dongsheng, Moore Malcolm J, Parulekar Wendy R and Koong Albert C. 20160708. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. : PloS one.

Harvard

Shultz D. B., Pai J., Chiu W., Ng K., Hellendag M. G., Heestand G., Chang D. T., Tu D., Moore M. J., Parulekar W. R. and Koong A. C. (20160708). A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. : PloS one.

MLA

Shultz David B, Pai Jonathan, Chiu Wayland, Ng Kendall, Hellendag Madeline G, Heestand Gregory, Chang Daniel T, Tu Dongsheng, Moore Malcolm J, Parulekar Wendy R and Koong Albert C. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. : PloS one. 20160708.